Intervention evidence check

TB-500 (thymosin beta-4): what the evidence actually shows

Medical review statusMedically reviewedReviewed by: Stem Plus medical teamReviewed on: 2026-08-29Last evidence update: 2026-08-29Methodology and editorial standards
Clinical review team: Dr Kamelia Milcheva, Hematologist · Dr Vadym Uvarov, Board-Certified Physician · Hepatobiliary Surgeon · Candidate of Medical SciencesEditorial responsibility: StemCellAtlas research teamEducational information only. This page does not provide medical advice, diagnosis or a treatment recommendation.

Peptide (research compound)

TB-500 (thymosin beta-4)
Status: TB-500 is the grey-market name for synthetic thymosin beta-4 fragments. Not approved for human use; prohibited for athletes under WADA rules.

Thymosin beta-4 is a real human protein with a serious research base — over 1,000 indexed papers, about 605 involving humans, including early-phase trials in wound healing and cardiac repair that never translated into an approved therapy. The vials sold online as “TB-500” are a different matter: unregulated fragments with no published human trials of their own.

PubMed footprint (2026-08-29): 1,074 indexed publications, 605 involving humans (search: "TB-500" OR thymosin beta-4).

What it is

Thymosin beta-4 is an actin-binding peptide involved in cell migration and tissue repair; it is present in nearly every human cell. Pharmaceutical programmes tested defined formulations for corneal healing, pressure ulcers and post-infarct cardiac repair through early-phase studies during the 2010s. TB-500, the product sold to consumers, is typically a synthetic fragment manufactured outside any pharmacopoeia.

What the research actually shows

Legitimate trials of pharmaceutical thymosin beta-4 produced mixed, mostly modest results, and development stalled — none reached approval. That history is often quoted as if it validated grey-market TB-500; it does not. No controlled human study of the consumer product exists, and fragment identity varies between vendors.

Risks and open questions

Thymosin beta-4 biology touches angiogenesis and cell migration — pathways that cut both ways in oncology. That is a reason for regulated trials, not casual self-injection. Sterility and dose accuracy of research-chemical vials are unverified, and athletes have tested positive for it.

FAQ

Is TB-500 the same as thymosin beta-4?

Not exactly. TB-500 products are synthetic fragments marketed under that name; pharmaceutical thymosin beta-4 was a defined drug candidate that never reached approval.

Did human trials of thymosin beta-4 succeed?

Early-phase trials in wound and cardiac repair showed modest or mixed results and the programmes stalled before approval.

Is TB-500 banned in sport?

Yes — it is prohibited by WADA and is a recurring cause of doping violations.

Sources & further reading

→ Evaluating a clinic that sells this? Build a provider question list

Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.

Explore all sections · Data & downloads